77 related articles for article (PubMed ID: 8554604)
1. The MDR1 downstream promoter contains sequence-specific binding sites for wild-type p53.
Strauss BE; Shivakumar C; Deb SP; Deb S; Haas M
Biochem Biophys Res Commun; 1995 Dec; 217(3):825-31. PubMed ID: 8554604
[TBL] [Abstract][Full Text] [Related]
2. The region 3' to the major transcriptional start site of the MDR1 downstream promoter mediates activation by a subset of mutant P53 proteins.
Strauss BE; Haas M
Biochem Biophys Res Commun; 1995 Dec; 217(1):333-40. PubMed ID: 8526930
[TBL] [Abstract][Full Text] [Related]
3. The core promoter region of the P-glycoprotein gene is sufficient to confer differential responsiveness to wild-type and mutant p53.
Zastawny RL; Salvino R; Chen J; Benchimol S; Ling V
Oncogene; 1993 Jun; 8(6):1529-35. PubMed ID: 8502478
[TBL] [Abstract][Full Text] [Related]
4. Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.
Takimoto R; El-Deiry WS
Oncogene; 2000 Mar; 19(14):1735-43. PubMed ID: 10777207
[TBL] [Abstract][Full Text] [Related]
5. p53 involvement in activation of the cytokeratin 8 gene in tumor cell lines.
Mukhopadhyay T; Roth JA
Anticancer Res; 1996; 16(1):105-12. PubMed ID: 8615594
[TBL] [Abstract][Full Text] [Related]
6. Analysis of p53 transactivation through high-affinity binding sites.
Chumakov AM; Miller CW; Chen DL; Koeffler HP
Oncogene; 1993 Nov; 8(11):3005-11. PubMed ID: 8414502
[TBL] [Abstract][Full Text] [Related]
7. Lack of P-glycoprotein expression by low-dose fractionated radiation results from loss of nuclear factor-kappaB and NF-Y activation in oral carcinoma cells.
Shareef MM; Brown B; Shajahan S; Sathishkumar S; Arnold SM; Mohiuddin M; Ahmed MM; Spring PM
Mol Cancer Res; 2008 Jan; 6(1):89-98. PubMed ID: 18234965
[TBL] [Abstract][Full Text] [Related]
8. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.
Mirza A; McGuirk M; Hockenberry TN; Wu Q; Ashar H; Black S; Wen SF; Wang L; Kirschmeier P; Bishop WR; Nielsen LL; Pickett CB; Liu S
Oncogene; 2002 Apr; 21(17):2613-22. PubMed ID: 11965534
[TBL] [Abstract][Full Text] [Related]
9. Transactivation of the human multidrug resistance (MDR1) gene promoter by p53 mutants.
Nguyen KT; Liu B; Ueda K; Gottesman MM; Pastan I; Chin KV
Oncol Res; 1994; 6(2):71-7. PubMed ID: 7949467
[TBL] [Abstract][Full Text] [Related]
10. Influence of exogenous ras and p53 on P-glycoprotein function in immortalized rodent fibroblasts.
Kopnin BP; Stromskaya TP; Kondratov RV; Ossovskaya VS; Pugacheva EN; Rybalkina EY; Khokhlova OA; Chumakov PM
Oncol Res; 1995; 7(6):299-306. PubMed ID: 8527864
[TBL] [Abstract][Full Text] [Related]
11. Interaction of human polyomavirus BK with the tumor-suppressor protein p53.
Shivakumar CV; Das GC
Oncogene; 1996 Jul; 13(2):323-32. PubMed ID: 8710371
[TBL] [Abstract][Full Text] [Related]
12. Enhanced expression of the human multidrug resistance 1 gene in response to UV light irradiation.
Uchiumi T; Kohno K; Tanimura H; Matsuo K; Sato S; Uchida Y; Kuwano M
Cell Growth Differ; 1993 Mar; 4(3):147-57. PubMed ID: 8466853
[TBL] [Abstract][Full Text] [Related]
13. c-Myc trans-activates the p53 promoter through a required downstream CACGTG motif.
Reisman D; Elkind NB; Roy B; Beamon J; Rotter V
Cell Growth Differ; 1993 Feb; 4(2):57-65. PubMed ID: 8494784
[TBL] [Abstract][Full Text] [Related]
14. Binding sequence-dependent regulation of the human proliferating cell nuclear antigen promoter by p53.
Shan B; Morris GF
Exp Cell Res; 2005 Apr; 305(1):10-22. PubMed ID: 15777783
[TBL] [Abstract][Full Text] [Related]
15. ETS1 and ETS2 in p53 regulation: spatial separation of ETS binding sites (EBS) modulate protein: DNA interaction.
Venanzoni MC; Robinson LR; Hodge DR; Kola I; Seth A
Oncogene; 1996 Mar; 12(6):1199-1204. PubMed ID: 8649821
[TBL] [Abstract][Full Text] [Related]
16. Additive effect between NF-kappaB subunits and p53 protein for transcriptional activation of human p53 promoter.
Benoit V; Hellin AC; Huygen S; Gielen J; Bours V; Merville MP
Oncogene; 2000 Sep; 19(41):4787-94. PubMed ID: 11032029
[TBL] [Abstract][Full Text] [Related]
17. KAI1 promoter activity is dependent on p53, junB and AP2: evidence for a possible mechanism underlying loss of KAI1 expression in cancer cells.
Marreiros A; Dudgeon K; Dao V; Grimm MO; Czolij R; Crossley M; Jackson P
Oncogene; 2005 Jan; 24(4):637-49. PubMed ID: 15580298
[TBL] [Abstract][Full Text] [Related]
18. p53-dependent suppression of uridine phosphorylase gene expression through direct promoter interaction.
Zhang D; Cao D; Russell R; Pizzorno G
Cancer Res; 2001 Sep; 61(18):6899-905. PubMed ID: 11559567
[TBL] [Abstract][Full Text] [Related]
19. Release of the p53-induced repression on thymidine kinase promoter by single p53-binding sequence.
Yuan JN; Liu BH; Lee H; Shaw YT; Chiou ST; Chang WC; Lai MD
Biochem Biophys Res Commun; 1993 Mar; 191(2):662-8. PubMed ID: 8384849
[TBL] [Abstract][Full Text] [Related]
20. The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.
McCoy C; McGee SB; Cornwell MM
Cell Growth Differ; 1999 Jun; 10(6):377-86. PubMed ID: 10392899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
